227 related articles for article (PubMed ID: 37877249)
1. The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
Cho YM; Furie R
Immunotherapy; 2024 Jan; 16(1):15-20. PubMed ID: 37877249
[TBL] [Abstract][Full Text] [Related]
2. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus.
Cho SK; Vazquez T; Werth VP
Expert Opin Investig Drugs; 2023 May; 32(5):345-353. PubMed ID: 37148249
[TBL] [Abstract][Full Text] [Related]
3. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA; van Vollenhoven RF; Kalunian K; Navarra S; Romero-Diaz J; Werth VP; Huang X; Clark G; Carroll H; Meyers A; Musselli C; Barbey C; Franchimont N;
N Engl J Med; 2022 Sep; 387(10):894-904. PubMed ID: 36069871
[TBL] [Abstract][Full Text] [Related]
4. Effect of
Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
Front Immunol; 2019; 10():275. PubMed ID: 30846987
[No Abstract] [Full Text] [Related]
5. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP; Furie RA; Romero-Diaz J; Navarra S; Kalunian K; van Vollenhoven RF; Nyberg F; Kaffenberger BH; Sheikh SZ; Radunovic G; Huang X; Clark G; Carroll H; Naik H; Gaudreault F; Meyers A; Barbey C; Musselli C; Franchimont N;
N Engl J Med; 2022 Jul; 387(4):321-331. PubMed ID: 35939578
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials.
Lim D; Kleitsch J; Werth VP
Expert Opin Emerg Drugs; 2023 Dec; 28(4):257-273. PubMed ID: 37860982
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous and systemic connections in lupus.
Maz MP; Michelle Kahlenberg J
Curr Opin Rheumatol; 2020 Nov; 32(6):583-589. PubMed ID: 32826479
[TBL] [Abstract][Full Text] [Related]
9. Emerging biologic therapies for systemic lupus erythematosus.
Kato H; Kahlenberg JM
Curr Opin Rheumatol; 2024 May; 36(3):169-175. PubMed ID: 38299618
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus.
Vazquez T; Patel J; Kodali N; Diaz D; Bashir MM; Chin F; Keyes E; Sharma M; Sprow G; Grinnell M; Dan J; Werth VP
J Invest Dermatol; 2024 Jun; 144(6):1262-1272.e7. PubMed ID: 38086428
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
Zhang YP; Wu J; Han YF; Shi ZR; Wang L
Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
Furie R; Werth VP; Merola JF; Stevenson L; Reynolds TL; Naik H; Wang W; Christmann R; Gardet A; Pellerin A; Hamann S; Auluck P; Barbey C; Gulati P; Rabah D; Franchimont N
J Clin Invest; 2019 Mar; 129(3):1359-1371. PubMed ID: 30645203
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice.
Patel J; Borucki R; Werth VP
Curr Rheumatol Rep; 2020 Aug; 22(10):69. PubMed ID: 32845411
[TBL] [Abstract][Full Text] [Related]
14. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
15. Role of neutrophils in cutaneous lupus erythematosus.
Yamamoto T
J Dermatol; 2024 Feb; 51(2):180-184. PubMed ID: 38009863
[TBL] [Abstract][Full Text] [Related]
16. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
17. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
[TBL] [Abstract][Full Text] [Related]
18. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus.
Soto JA; Melo-González F; Riedel CA; Bueno SM; Kalergis AM
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142624
[TBL] [Abstract][Full Text] [Related]
20. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.
Pellerin A; Otero K; Czerkowicz JM; Kerns HM; Shapiro RI; Ranger AM; Otipoby KL; Taylor FR; Cameron TO; Viney JL; Rabah D
EMBO Mol Med; 2015 Apr; 7(4):464-76. PubMed ID: 25762615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
